Monday, March 30th7.1°C
25326
25546

Vancouver Ebola drug developer sees wild swings in stock price amid outbreak

A Canadian company developing an experimental Ebola drug has seen its stock swing wildly in recent days, but analysts say the underlying outlook for Tekmira Pharmaceuticals Corp. hasn't been swayed by the outbreak of the deadly virus.

Vancouver-based Tekmira's stock (TSX:TMK) closed down nearly 22 per cent at $20.25 on the Toronto Stock Exchange on Tuesday.

Tuesday's drop followed a nearly 60 per cent surge over the previous two trading sessions.

"The recent trading activity in the stock has been more trading driven than investment driven," said Doug Loe, an analyst with Euro Pacific Canada.

But longer term, Loe said he sees upside potential in the wider array of products Tekmira has in the development pipeline.

Tekmira announced last Thursday that the U.S. Food and Drug Administration had "verbally confirmed" it would relax a clinical hold on its TKM-Ebola drug, potentially enabling its use in individuals stricken with the deadly virus.

The outbreak has killed more than 1,000 people in West Africa since March.

Jason Kolbert, an analyst at Maxim Group in New York, said investors were "freaking out" because a Spanish priest, who was reportedly treated with another Ebola drug called ZMapp, died Tuesday in Madrid after being flown out of Liberia.

Kolbert said he sees "no relationship whatsoever" between the prospects for ZMapp and TKM-Ebola, as the two treatments take completely different approaches.

"However, just as the people were focused on Ebola and kind of drove Tekmira shares higher, now you're seeing selling in the stock. It's just volatility associated with a lot of, I'd say, retail buying of Ebola biodefence names."

"It's a pendulum. It tends to overreact."

The World Health Organization said Tuesday that it is ethical to use untested Ebola drugs, but that countries using experimental treatments have a moral obligation to collect data so the world can learn how to combat the virus.

The statement makes no reference to the fact that these experimental therapies are currently in short supply.

On Monday, ZMapp's San Diego-based developer, Mapp Biopharmaceutical, said it had exhausted its supply of the product, components of which were created at Canada's National Microbiology Laboratory in Winnipeg. Experts have said it will take three or four months for another small batch of ZMapp to be made.

That drug was given to two American relief workers who contracted Ebola in Liberia and both appear to be recovering.

It's unclear how much TKM-Ebola Tekmira has in stock, or how quickly manufacturing of the drug can be ramped up.

Tekmira says its drug, which targets the cells where the virus replicates, is the most advanced Ebola treatment option in development.

The timelines for making TKM-Ebola available for "compassionate use" — providing a drug that has not been formally approved on an emergency basis — wouldn't be too long, Loe said.

"We'd be measuring those in days to weeks rather than weeks to months, as would be the case for other biologics that could be developed in this space."

Last week, Tekmira CEO Mark Murray said the company was pleased the FDA considered the risks and rewards of potentially using TKM Ebola in infected patients.

"We have been closely watching the Ebola virus outbreak and its consequences and we are willing to assist with any responsible use of TKM-Ebola. The foresight shown by the FDA removes one potential roadblock to doing so," he said in a release.

Tekmira has a $140-million contract from the U.S. government to develop TKM-Ebola but last month a small human trial of the experimental drug was put on hold after safety issues emerged.

Restrictions remain on testing the drug on healthy volunteers, but Murray said the company is "focused on an expedient resolution" on that matter.

In a research note last week, analysts with RBC Capital Markets called the FDA move an "incremental positive" for Tekmira.

"Bottom line, we've confirmed with the company this lifts the obstacle in case one seeks the drug for compassionate use and they do have supply of some drug intended for clinical trials. To meet the much larger demand of the broader outbreak, they would have to ramp up manufacturing, which could take months," they wrote.

"While we acknowledge there is the potential for (Tekmira) to land significant revenues due to its Ebola program, this should only be considered a long-term upside opportunity as visibility is very low and predicting what happens with pandemic outbreaks and government contracts can be risky."

Adrian Mastracci, with KCM Wealth Management, said he'd consider Tekmira an "aggressive" investment bet.

"These guys could be a Cinderella story if something works out," said the Vancouver-based portfolio manager.

He said the recent share price fluctuation has been driven by "pure emotion."

"It's got nothing to do with logic."

Follow @LaurenKrugel on Twitter

The Canadian Press


Read more Business News

24910


Recent Trending




Today's Market
S&P TSX14931.96+119.54
S&P CDNX683.68+2.25
DJIA17975.48+262.82
Nasdaq4932.83+41.61
S&P 5002081.55+20.53
CDN Dollar0.7890-0.004
Gold1196.30-8.80
Oil48.82-0.05
Lumber282.60-3.60
Natural Gas2.62-0.05

 
Okanagan Companies
Pacific Safety0.125-0.005
Knighthawk0.010.00
QHR Technologies Inc1.49-0.01
Cantex0.03-0.01
Anavex Life Sciences0.219+0.000
Metalex Ventures0.04-0.01
Russel Metals24.74+0.24
Copper Mountain Mining1.13+0.00
Colorado Resources0.125+0.010
ReliaBrand Inc0.006-0.001
Sunrise Resources Ltd0.045+0.000
Mission Ready Services0.255+0.020
Decisive Dividend Corporation1.80+0.02

 



24393

FEATURED Property
1818890259 - 2001 Hwy 97
3 bedrooms 1 baths
$78,900
more details
image2image2image2
Click here to feature your property
Please wait... loading


Down payment

If you have less than 20% down payment, mortgage insurance is required through Canada Mortgage & Housing (CMHC), Genworth or Canada Guaranty. Homeowners no longer need the minimum 5% down payment ...


CRA Notice of Assessment

Many Canadians rush to file their taxes on time each year and don’t think about it until the next year. One of the most overlooked notices received from the CRA annually is the annual Notice of ...


Medical confidential?

If ICBC asks your doctor for your information you may wonder: Can ICBC ask my doctor for my medical information? Can ICBC request a medical report from my doctor without my consent? What is ICBC entit...

_





25482


Member of BC Press Council


25534